Treatment of Guillain-Barré syndrome with anti-T cell monoclonal antibodies.

The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine (Baltimore) (1969) 4.72

Inflammatory demyelinating peripheral neuropathies associated with human T-cell lymphotropic virus type III infection. Ann Neurol (1987) 2.05

Guillain-Barré syndrome and Hodgkin's disease: three cases with immunological studies. Ann Neurol (1977) 1.84

Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur J Immunol (1982) 1.37

Impact of Orthoclone OKT3 on liver transplantation. Transplant Proc (1987) 1.36

Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected]. N Engl J Med (1989) 1.34

Clinical correlation with anti-peripheral-nerve myelin antibodies in Guillain-Barré syndrome. Ann Neurol (1986) 1.33

T cell activation in Guillain-Barré syndrome and in MS: elevated serum levels of soluble IL-2 receptors. Neurology (1990) 1.06

Passive transfer studies in Guillain-Barré polyneuropathy. Neurology (1982) 1.01

Immunosuppression and the Guillain-Barré syndrome. Arch Neurol (1970) 0.90

Ultrastructural effects of Guillain-Barré serum in cultures containing only rat Schwann cells and dorsal root ganglion neurons. Brain Res (1987) 0.85

In-vivo anti-CD3 treatment of autoimmune patients. Lancet (1989) 0.85

Cerebrospinal fluid inflammation during OKT3 therapy. Lancet (1986) 0.80

Modulation of experimental allergic neuritis in rats by in vivo treatment with monoclonal anti T cell antibodies. J Neurol Sci (1988) 0.79

Severe axonal degeneration in acute Guillain-Barré syndrome: evidence of two different mechanisms? J Neurol Sci (1993) 0.88

Complement depletion suppresses Lewis rat experimental allergic neuritis. Brain Res (1987) 0.77